These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36907878)

  • 1. Homeobox D9 drives the malignant phenotypes and enhances the Programmed death ligand-1 expression in non-small cell lung cancer cells via binding to Angiopoietin-2 promoter.
    He J; Jiang M; Liu J; Zhu R; Lv W; Lian R; Yang Y; Wang R
    World J Surg Oncol; 2023 Mar; 21(1):93. PubMed ID: 36907878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter.
    Hirao N; Iwata T; Tanaka K; Nishio H; Nakamura M; Morisada T; Morii K; Maruyama N; Katoh Y; Yaguchi T; Ohta S; Kukimoto I; Aoki D; Kawakami Y
    Gynecol Oncol; 2019 Nov; 155(2):340-348. PubMed ID: 31477279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 4. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 6. HOXD9 contributes to the Warburg effect and tumor metastasis in non-small cell lung cancer via transcriptional activation of PFKFB3.
    Wan K; Shao J; Liu X; Cai Y; Xu Y; Li L; Xiong L; Liang S
    Exp Cell Res; 2023 Jun; 427(1):113583. PubMed ID: 37004946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
    Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
    Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer.
    Pan X; Zhang W; Wang L; Guo H; Zheng M; Wu H; Weng Q; He Q; Ding L; Yang B
    Mol Oncol; 2023 Dec; 17(12):2659-2674. PubMed ID: 37606530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcription Factor Homeobox D9 Drives the Malignant Phenotype of HPV18-Positive Cervical Cancer Cells via Binding to the Viral Early Promoter.
    Hayashi S; Iwata T; Imagawa R; Sugawara M; Chen G; Tanimoto S; Sugawara Y; Tanaka I; Matsui T; Nishio H; Nakamura M; Katoh Y; Mori S; Kukimoto I; Aoki D
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.
    Huang Y; Xia L; Tan X; Zhang J; Zeng W; Tan B; Yu X; Fang W; Yang Z
    Cell Mol Biol Lett; 2022 Jun; 27(1):43. PubMed ID: 35658874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
    Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
    Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
    Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
    Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S; Wang K; Huang X; Zhao Z; Zhao Z
    Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circ_0092012 knockdown restrains non-small cell lung cancer progression by inhibiting cell malignant phenotype and immune escape through microRNA-635/programmed death ligand 1 axis.
    Yan J; Zhu J; Zhu X; Liu H; Chen G
    Bioengineered; 2022 May; 13(5):13929-13943. PubMed ID: 35723188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.